Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2026-02-23 @ 8:09 PM
Study NCT ID:
NCT03769467
Status:
TERMINATED
Last Update Posted:
2024-11-14
First Post:
2018-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Sponsor:
Atara Biotherapeutics
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Nasopharyngeal Carcinoma (NPC) | View |
| None | NPC | View |
| None | Nasopharyngeal Cancer | View |
| None | Nose Cancer | View |
| None | Epstein-Barr Virus (EBV) | View |
| None | Epstein-Barr Virus Viremia | View |
| None | EBV-associated NPC | View |
| None | Allogeneic, off-the-shelf T-cell | View |
| None | immunotherapy | View |
| None | Head and Neck Cancer | View |
| None | Carcinoma | View |
| None | Nasopharyngeal Neoplasms | View |
| None | Neoplasms, Glandular and Epithelial | View |
| None | Neoplasms by Histologic Type | View |
| None | Neoplasms | View |
| None | Pharyngeal Neoplasms | View |
| None | Otorhinolaryngologic Neoplasms | View |
| None | Head and Neck Neoplasms | View |
| None | Neoplasms by Site | View |
| None | Nasopharyngeal Diseases | View |
| None | Pharyngeal Diseases | View |
| None | Stomatognathic Diseases | View |
| None | Otorhinolaryngologic Diseases | View |
| None | Pembrolizumab | View |
| None | Programmed death-1 (PD-1) | View |
| None | Programmed death-ligand 1(PD-L1) | View |